# clm_ECBF22AE9226

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_research_and_development  
value: 390,330,000 United States dollar  
valid_from: 2015-06-30  
valid_to: 2015-09-30  
published: 2015-08-04  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_FBAC011B1148  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly research and development: 390,330,000 United States dollar", as of 2015-06-30 (until 2015-09-30). Claim clm_ECBF22AE9226, https://asof.is/claim/clm_ECBF22AE9226, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2015, filed 2015-08-04  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000153217615000029/0001532176-15-000029-index.htm (primary, SEC EDGAR 10-Q Q2 FY2015, published 2015-08-04)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_research_and_development | 343,113,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_ECBF22AE9226](/claim/clm_ECBF22AE9226.md) | [clm_8ACDB2D459CA](/claim/clm_8ACDB2D459CA.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.